CROSSJECT Completes Financing with Vatel Capital
CROSSJECT, a pioneer in specialty pharmaceuticals, has successfully secured €5 million in funding through a strategic agreement with Vatel Capital. Utilizing the innovative ZENEO® needle-free auto-injector technology, CROSSJECT is advancing its product portfolio, particularly the ZEPIZURE® injectable designed for epilepsy treatment.
Details of the Financing
The financing was executed via a reserved issuance of convertible bonds across three tranches, enabling flexibility for the company. The bonds feature attractive interest rates that vary from 7.5% to 9.5% over a term of 3 to 5 years, convertible at €2.65 per share. This mechanism potentially translates into the issuance of 1,886,790 new shares, which would represent about 3.52% of the company’s share capital on a non-diluted basis.
CEO's Perspective on the Financing
Patrick Alexandre, CEO of CROSSJECT, expressed his satisfaction with the funding, emphasizing the importance of this financing in maintaining flexibility as the company navigates regulatory hurdles related to ZEPIZURE®'s Emergency Use Authorization application with the U.S. authorities.
Regulatory Activities and Goals
In collaboration with the U.S. Biomedical Advanced Research and Development Authority (BARDA), CROSSJECT is actively submitting data to further its regulatory approval processes. This includes necessary audits to ensure manufacturing facilities meet U.S. FDA compliance standards. The company aims to achieve a rapid EUA approval shortly, given ongoing progress in these regulatory activities.
Allocation of Funds from the Financing
The allocation of the proceeds from this financing is balanced, with approximately 50% directed towards the development and registration of ZEPIZURE®, covering associated operational and research and development expenses. The remaining 50% will fund additional R&D projects, enhance manufacturing capabilities, and cover other corporate needs, including repayments to financial creditors.
Future Financing Considerations
With the net proceeds of around €4.9 million, CROSSJECT is confident in its ability to meet working capital needs until achieving its regulatory objectives. The company continues to explore both dilutive and non-dilutive financing opportunities to extend its financial runway. Additionally, the potential for raised funds from stock warrants is significant.
Impact of Convertible Bonds on Company Shares
The Convertible Bonds present both opportunities and challenges regarding share dilution. Should all bonds be converted, CROSSJECT would face changes in shareholder equity distribution. The company has prepared for the implications of such conversions in terms of capital structure and potential share prices.
Company's Future Prospects
CROSSJECT remains focused on its strategic trajectory. The R&D efforts surrounding ZEPIZURE® position the company for growth, especially as it prepares applications for additional drug indications using its ZENEO® platform. Alongside ZEPIZURE®, the company is also advancing other therapeutic solutions aimed at emergency healthcare needs.
Conclusion and Contact Information
This latest financing signifies a robust endorsement of CROSSJECT's innovative capacity and potential within the specialty pharmaceuticals sector. For further inquiries, stakeholders can reach the company's investor relations team via email or visit their official website.
Frequently Asked Questions
What is CROSSJECT known for?
CROSSJECT specializes in developing products for emergency situations, particularly using its ZENEO® auto-injector technology.
How much funding did CROSSJECT secure?
The company completed a €5 million financing with Vatel Capital.
What is ZEPIZURE®?
ZEPIZURE® is an injectable product aimed at treating epileptic seizures, currently in advanced regulatory development.
What are the terms of the Convertible Bonds?
The Convertible Bonds bear interest rates between 7.5% and 9.5% and are convertible at €2.65 per share.
How will the funds be used?
The proceeds will support the development of ZEPIZURE® and other R&D initiatives, as well as general corporate needs.
